FindTrial
Sign In

Prospectiv and effective EBV viral monitoring to predict PTLD in patients undergoing HSCT

Prospectiv and effective EBV viral monitoring to predict PTLD in patients undergoing allogeneic hematopoietic stem cell transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-12002650
Enrollment
Unknown
Registered
2014-09-21
Start date
2011-09-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EBV infection after hematopoietic stem cell transplantation

Interventions

1:haploid / unrelated hematopoietic stem cell transplantation

Sponsors

People's Hospital Peking University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 65 Years

Inclusion criteria

Inclusion criteria: age: 2-65y; indicated for related haploidentical/unrelated HSCT; signed consent form

Exclusion criteria

Exclusion criteria: unconsented

Design outcomes

Primary

MeasureTime frame
EBV;—

Contacts

Public ContactChen Yuhong
chch9929@vip.sina.com+86 10 88324952

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026